Bulletin
Investor Alert

New York Markets Close in:

Market Snapshot Winners and Losers

Intellia Therapeutics Inc.

NAS: NTLA

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Intellia Therapeutics Inc.

Market open

 --Real time quotes

Feb 1, 2023, 10:24 a.m.

NTLA
/zigman2/quotes/207821052/composite

$

41.83

Change

-0.61 -1.44%

Volume

Volume 183,046

Real time quotes

/zigman2/quotes/207821052/composite

Previous close

$ 42.44

$ 41.83

Change

-0.61 -1.44%

Day low

Day high

$41.83

$43.71

Open

52 week low

52 week high

$32.44

$104.87

Open

Company Description

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in t...

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Valuation

Price to Sales Ratio

253.61

Price to Book Ratio

8.47

Enterprise Value to EBITDA

-10.52

Enterprise Value to Sales

53.40

Efficiency

Total Asset Turnover

0.03

Liquidity

Current Ratio

6.11

Quick Ratio

6.11

Cash Ratio

5.95

Profitability

Gross Margin

79.15

Operating Margin

-810.37

Pretax Margin

-810.49

Net Margin

-810.49

Return on Assets

-27.19

Return on Equity

-34.18

Return on Total Capital

-31.87

Capital Structure

Total Debt to Total Assets

5.72

Officers and Executives

Name Age Officer Since Title
Dr. John M. Leonard 63 2014 Director & Chief Medical Officer
Mr. Glenn Goddard 48 2018 Executive VP, Chief Financial & Accounting Officer
Dr. Laura Sepp-Lorenzino 60 2019 Chief Scientific Officer & Executive VP
Dr. Eliana Clark - - Senior Vice President-Technical Operations
Dr. David Lebwohl - 2020 Chief Medical Officer & Executive Vice President

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/05/2023 Laura Sepp-Lorenzino
EVP, Chief Scientific Officer 		689   Disposition at $39.1 per share. 26,939
01/05/2023 Laura Sepp-Lorenzino
EVP, Chief Scientific Officer 		1,641   Disposition at $38.22 per share. 62,719
01/04/2023 John M. Leonard
President and CEO; Director 		6,673   Disposition at $37.21 per share. 248,302
01/04/2023 David Lebwohl
EVP, Chief Medical Officer 		2,574   Disposition at $37.21 per share. 95,778
01/04/2023 James Basta
EVP, General Counsel 		1,138   Disposition at $37.21 per share. 42,344
01/04/2023 Laura Sepp-Lorenzino
EVP, Chief Scientific Officer 		2,508   Disposition at $37.21 per share. 93,322
01/04/2023 Derek Hicks
EVP, Chief Business Officer 		1,812   Disposition at $37.21 per share. 67,424
01/04/2023 Glenn Goddard
EVP, Chief Financial Officer 		2,427   Disposition at $37.21 per share. 90,308
01/04/2023 Eliana Clark
EVP, Chief Technical Officer 		1,692   Disposition at $37.21 per share. 62,959
01/03/2023 Eliana Clark
EVP, Chief Technical Officer 		231   Disposition at $34.48 per share. 7,964
01/01/2023 John M. Leonard
President and CEO; Director 		7,848   Derivative/Non-derivative trans. at $0 per share. 0
01/01/2023 David Lebwohl
EVP, Chief Medical Officer 		3,187   Derivative/Non-derivative trans. at $0 per share. 0
01/01/2023 Laura Sepp-Lorenzino
EVP, Chief Scientific Officer 		3,500   Derivative/Non-derivative trans. at $0 per share. 0
01/01/2023 Glenn Goddard
EVP, Chief Financial Officer 		3,062   Derivative/Non-derivative trans. at $0 per share. 0
07/01/2022 Eliana Clark
EVP, Chief Technical Officer 		105   Disposition at $51.74 per share. 5,432
06/14/2022 Fred Ehrenkranz Cohen
Director 		5,197   Award at $0 per share. 0
06/14/2022 Caroline D. Dorsa
Director 		5,197   Award at $0 per share. 0
06/14/2022 Muna Bhanji
Director 		2,014   Award at $0 per share. 0
06/14/2022 John Francis Crowley
Director 		5,197   Award at $0 per share. 0
06/14/2022 Jean-Francois B. Formela
Director 		5,197   Award at $0 per share. 0
06/14/2022 Frank A. G. M. Verwiel
Director 		5,197   Award at $0 per share. 0
06/14/2022 Jesse L. Goodman
Director 		5,197   Award at $0 per share. 0
06/14/2022 Georgia Keresty
Director 		5,197   Award at $0 per share. 0
04/28/2022 Muna Bhanji
Director 		7,954   Award at $0 per share. 0
03/01/2022 John M. Leonard
President and CEO; Director 		40,990   Award at $0 per share. 0
03/01/2022 David Lebwohl
EVP, Chief Medical Officer 		13,816   Award at $0 per share. 0
03/01/2022 Glenn Goddard
EVP, Chief Financial Officer 		12,720   Award at $0 per share. 0
03/01/2022 Eliana Clark
EVP, Chief Technical Officer 		10,527   Award at $0 per share. 0
01/03/2022 Derek Hicks
EVP, Chief Business Officer 		19,118   Award at $0 per share. 0
01/01/2022 John M. Leonard
President and CEO; Director 		2,493   Disposition at $112.26 per share. 279,864
01/01/2022 David Lebwohl
EVP, Chief Medical Officer 		1,051   Disposition at $112.24 per share. 117,964
01/01/2022 Glenn Goddard
EVP, Chief Financial Officer 		1,013   Disposition at $112.24 per share. 113,699
01/01/2022 John M. Leonard
President and CEO; Director 		7,848   Derivative/Non-derivative trans. at $0 per share. 0
01/01/2022 David Lebwohl
EVP, Chief Medical Officer 		3,187   Derivative/Non-derivative trans. at $0 per share. 0
01/01/2022 Glenn Goddard
EVP, Chief Financial Officer 		3,062   Derivative/Non-derivative trans. at $0 per share. 0
/news/latest/company/us/ntla

MarketWatch News on NTLA

  1. Intellia Therapeutics stock price target cut to $131 from $173 at Stifel Nicolaus

    7:49 a.m. Jan. 6, 2023

    - Tomi Kilgore

  2. Intellia Therapeutics started at overweight with $84 stock price target at Morgan Stanley

    8:41 a.m. Oct. 11, 2022

    - Tomi Kilgore

  3. What’s Next for the Healthcare Industry, and How to Invest

    8:47 a.m. Sept. 25, 2022

    - Barron's Online

  6. 11 Cheap Tech Stocks to Consider After the Earnings Deluge

    3:32 p.m. Aug. 25, 2022

    - Barron's Online

  7. 10 Stocks Driving the Biotech Resurgence

    7:49 a.m. Aug. 18, 2022

    - Barron's Online

  8. Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead

    3:25 p.m. June 23, 2022

    - Barron's Online

  9. Intellia Therapeutics started at market perform with $54 stock price target at BMO Capital

    11:22 a.m. June 17, 2022

    - Tomi Kilgore

  13. Intellia Therapeutics upgraded to outperform from perform at Oppenheimer

    7:28 a.m. Feb. 7, 2022

    - Tomi Kilgore

  16. Beam Gets FDA Nod for First Gene-Editing Trial

    8:10 a.m. Nov. 9, 2021

    - Barron's Online

  17. Prime Is the Newest Gene Editing, and It's Getting Better

    6:11 p.m. Oct. 20, 2021

    - Barron's Online

  19. This Fund Is Winning Big by Betting on Stocks That Help Humanity

    6:37 a.m. Sept. 27, 2021

    - Barron's Online

  20. Intellia Therapeutics started at buy with $173 stock price target at Stifel Nicolaus

    6:59 a.m. Sept. 24, 2021

    - Tomi Kilgore

  21. Loading more headlines...
/news/nonmarketwatch/company/us/ntla

Other News on NTLA

  1. IDNA: Healthcare Dashboard For November

    12:26 p.m. Nov. 16, 2022

    - Seeking Alpha

  2. ARKK Bears Are Losing Momentum

    8:04 p.m. Nov. 13, 2022

    - Seeking Alpha

  3. Intellia Therapeutics (NTLA) Investor Presentation - Slideshow

    11:30 p.m. Nov. 9, 2022

    - Seeking Alpha

  6. Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss

    12:20 p.m. Nov. 4, 2022

    - Zacks.com

  8. Editas Medicine: Q3 Update And 2 Clinical Catalysts To Watch

    6:45 a.m. Nov. 4, 2022

    - Seeking Alpha

  16. Prime Medicine: CRISPR 3.0 Company

    6:52 p.m. Oct. 24, 2022

    - Seeking Alpha

  18. RGA Investment Advisors Q3 2022 Investment Commentary

    10:45 a.m. Oct. 23, 2022

    - Seeking Alpha

  20. GNOM: ETF Review And Healthcare Dashboard For October

    6:01 p.m. Oct. 15, 2022

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Intellia Therapeutics, Inc.

40 Erie Street

Suite 130

Cambridge, Massachusetts 02139

Phone

1 8572856200

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

View SEC Filings

Revenue

$33.05M

Net Income

$-267.89M

Employees

485.00

Annual Report for NTLA

/news/pressrelease/company/us/ntla

Press Releases on NTLA

  21. Loading more headlines...
Link to MarketWatch's Slice.